News

PipelineReview.com1h
FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response
BASEL, Switzerland I August 11, 2025 I FoRx Therapeutics, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, today ...
PipelineReview.com2h
AMI Pharm Advances AYP-101 to Phase 3, Redefining Fat-Reduction Injectable drug with Patient Comfort in Focus
SEOUL, South Korea I August 11, 2025 I AMI Pharm, a biotechnology company focused on aesthetic and therapeutic innovations, announced today that its lead ...
PipelineReview.com2h
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
EAST HANOVER, NJ, USA I August 11, 2025 I Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults ...
PipelineReview.com2h
Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy
HONG KONG, China I August 10, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, ...
PipelineReview.com2h
Target selection in drug discovery: new service offering with predefined evaluation packages
STUTTGART, Germany I August 11, 2025 I Selecting the right target remains the most important decision to make in drug discovery and has to be seen in light of ...
PipelineReview.com1d
RemeGen’s Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA
YANTAI, China I August 8, 2025 I On August 8th, RemeGen Co., Ltd. (688331.SH/09995.HK) announces clearance of IND application by Food and Drug Administration ...
PipelineReview.com1d
U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
RIDGEFIELD, CT, USA and INGELHEIM, Germany I August 08, 2025 I Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) has been approved by the U.S. Food and ...
PipelineReview.com3d
REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy
ROCKVILLE, MD, USA I August 7, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today announced it will initiate a pivotal Phase IIb/III clinical trial for ...
PipelineReview.com3d
Lilly’s oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity
In ATTAIN-1, the investigational once-daily oral pill showed significant efficacy, and a safety and tolerability profile consistent with injectable GLP-1 ...
PipelineReview.com3d
Palleon Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of E-602 (HLX79), a Potential First-In-Class Treatment for Active Glomerulonephritis
WALTHAM, MA, USA I August 07, 2025 I Palleon Pharmaceuticals, a company pioneering glyco-immunology drug development to treat autoimmune diseases and cancer, ...
PipelineReview.com3d
K36 Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for KTX-2001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Announces ...
With this clearance, KTX-2001 becomes the second NSD2 inhibitor from K36 to advance into clinical development. This Phase 1 program will evaluate KTX-2001 both as a monotherapy and in combination with ...
PipelineReview.com3d
CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings
BERKELEY HEIGHTS, NJ, USA I August 07, 2025 I CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing ...